Novocure (NVCR) news
Recent news
Novocure Q2 EPS USD -0.13
On July 23, 2026, Novocure (NVCR) reported its Q2 2026 earnings, posting an earnings per share (EPS) of -$0.13. This result marked an improvement compared to the Q1 2026 EPS of -$0.62, which missed estimates by 26.53% . The Q2 EPS, however, was not accompanied by an analyst estimate for comparison.…
AInvest Wire · Jul 23, 2026Novocure updates FY2026 guidance
AInvest Wire · Jul 23, 2026Novocure Q2 pretax profit USD -12.452 million
AInvest Wire · Jul 23, 2026Novocure Ltd: JPMorgan resumes coverage with neutral rating; target price $17
AInvest Wire · Jul 13, 2026Novocure - to launch Optune Pax in Germany in coming weeks
Novocure (NASDAQ: NVCR) is preparing to launch its Optune Pax® device in Germany in the coming weeks, following the recent CE Mark approval for the treatment of locally advanced pancreatic cancer. The CE Mark was granted based on results from the Phase 3 PANOVA-3 trial, which demonstrated…
AInvest Wire · Jun 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.